[HTML][HTML] Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab

A Gupta, Y Gonzalez-Rojas, E Juarez… - … England Journal of …, 2021 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial

JR Sims, JA Zimmer, CD Evans, M Lu, P Ardayfio… - Jama, 2023 - jamanetwork.com
Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess
efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid …

Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial

A Gupta, Y Gonzalez-Rojas, E Juarez, MC Casal… - Jama, 2022 - jamanetwork.com
Importance Older patients and those with comorbidities who are infected with SARS-CoV-2
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …

Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial

…, R Varughese, Y Gonzalez-Rojas… - JAMA internal …, 2022 - jamanetwork.com
Importance Systemic corticosteroids are commonly used in treating severe COVID-19.
However, the role of inhaled corticosteroids in the treatment of patients with mild to moderate …

Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double …

…, B Ninov, Y Gonzalez-Rojas… - Clinical Infectious …, 2021 - academic.oup.com
Background The development of novel broad-spectrum antibiotics, with efficacy against both
gram-positive and gram-negative bacteria, has the potential to enhance treatment options …

Effect of the neutralizing SARS-CoV-2 antibody sotrovimab in preventing progression of COVID-19: a randomized clinical trial

A Gupta, Y Gonzalez-Rojas, E Juarez, MC Casal… - medRxiv, 2021 - medrxiv.org
Importance Older patients and those with underlying comorbidities infected with SARS-CoV-2
may be at increased risk of hospitalization and death from COVID-19. Sotrovimab is a …

Intramuscular vs intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized noninferiority clinical trial

…, J Acloque, A Free, Y Gonzalez-Rojas… - Open forum …, 2023 - academic.oup.com
Background Convenient administration of coronavirus disease 2019 (COVID-19) treatment
in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal …

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab (preprint)

A Gupta, Y Gonzalez-Rojas, E Juarez, MC Casal… - 2021 - pesquisa.bvsalud.org
Background: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-…

A randomized controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections

BM Clemency, R Varughese, Y Gonzalez-Rojas… - MedRxiv, 2021 - medrxiv.org
Importance Systemic corticosteroids are commonly used in the treatment of severe COVID-19.
However, their role in the treatment of patients with mild to moderate disease is less clear. …

[HTML][HTML] 1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment …

…, MT Perez-Rodríguez, Y Gonzalez-Rojas… - Open Forum …, 2022 - ncbi.nlm.nih.gov
… Anil K Gupta, MD, Maria Teresa Perez-Rodríguez, MD, Yaneicy Gonzalez-Rojas, MD,
Moti Ramgopal, MD, FACP, FIDSA, Almena Free, MD, Jennifer Han, MD, Jennifer Moore …